MOSCOW, Nov. 11, 2013 /PRNewswire/ -- Executive
leadership at Rafarma Pharmaceuticals (OTC:RAFA), recently met with
the Governor of Lipetsk, Oleg
Korolev, along with several government economic development
representatives, including the Trade mission of the Russian Federation in Great Britain and announced plans for British
investment in the region to create a "biopharmaceutical cluster" in
Terbuny. The parties signed a project initiative to increase growth
of the pharmaceutical industry in the region, finalize British
investment and obtain manufacturing contracts for Rafarma and its
biotech neighbors. As a certified and operating pharmaceutical
manufacturer, Rafarma will be the lead company in this venture.
Governor Korolev described Rafarma as one of the best
pharmaceutical enterprises of the Russian
Federation, and praised the plant's full compliance with
International Good Manufacturing Practices.
"Rafarma's state-of-the-art pharmaceutical plant in Terbuny has
become the flashpoint for biopharma investment in Terbuny, Rafarma
is leading the way," stated RAFA CEO Dave
Anderson.
About Rafarma Pharmaceuticals, Inc.
Operating from a new 270,000 square-foot state-of-the-art
manufacturing and distribution facility in Russia, Rafarma Pharmaceuticals produces
generic antibiotics and specialty pharmaceuticals in addition to
its own line of proprietary products that are approved by the
Ministry of Health of Russian
Federation. For the last three years, the Russian Government
has been highly focused on bolstering the development of nation's
domestic pharmaceutical industry. Rafarma Pharmaceuticals' mission
is to work with the auspices of aggressive federal initiatives to
fast-track the modernization of Russia's pharmaceutical industry.
For more information on Rafarma Pharmaceuticals, visit:
http://www.rafarma.com
Safe Harbor Statement
Matters discussed in this press release contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. When used in this press release, the words
"anticipate," "believe," "estimate," "may," "intend," "expect" and
similar expressions identify such forward-looking statements.
Actual results, performance or achievements could differ materially
from those contemplated, expressed or implied by the
forward-looking statements contained herein. These forward-looking
statements are based largely on the expectations of the Company and
are subject to a number of risks and uncertainties. These include,
but are not limited to: the impact of economic, competitive and
other factors affecting the Company and its operations, markets,
product, and distributor performance.
RELATED LINKS
Website: www.Rafarma.com
Facebook: www.facebook.com/Rafarmainfo
Twitter: www.twitter.com/Rafarmainfo
Contact:
David Anderson
1-801-210-7135
info@rafarma.com
SOURCE Rafarma Pharmaceuticals, Inc.
